David A. Siegel Navidea Biopharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $1.1 $7,560 - $13,200	-12,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.72 - $1.2 $35,568 - $59,280	-49,400 Reduced 80.46%	12,000 $9,000
Q4 2021 Feb 14, 2022	SELL	$1.0 - $1.82 $35,700 - $64,974	-35,700 Reduced 36.77%	61,400 $61,000
Q3 2021 Nov 15, 2021	SELL	$1.53 - $1.85 $85,964 - $103,944	-56,186 Reduced 36.65%	97,100 $170,000
Q2 2021 Aug 16, 2021	BUY	$1.55 - $2.15 $39,968 - $55,439	25,786 Added 20.22%	153,286 $281,000

Q1 2021 May 17, 2021	BUY	$1.99 - $2.9 $99,500 - $145,000	50,000 Added 64.52%	127,500 $258,000
Q4 2020 Feb 16, 2021	BUY	$1.88 - $2.84 $68,620 - $103,660	36,500 Added 89.02%	77,500 $167,000
Q3 2020 Nov 16, 2020	BUY	$2.69 - $4.95 $110,290 - $202,950	41,000 New	41,000 $111,000

10.4K

Ticker NAVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,150,900
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.